Mobile

A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Copeg...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-009608-38

A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Copegus for 12 or 24 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety, tolerability, and effect on virologicalresponse of a 12 and 24-week duration of RO5190591 incombination with Pegasys and Copegus compared to thecombination of Pegasys and Copegus alone in treatment-naïvepatients with chronic hepatitis C genotype 1 virus infection

Critère d'inclusion

  • Chronic Hepatitis C Genotype 1 Virus Infection (Treatment-Naïve Patients)

Liens